| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3474163988bef091f57392c448f942b9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-20134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-20122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-235
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861 |
| filingDate |
1991-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_790c7e4c68fa2f9f8d2b120640f3bd2c |
| publicationDate |
1994-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
HU-T65368-A |
| titleOfInvention |
Vaccines |
| abstract |
A recombinant adenovirus acting as a vector for an antigen-producing gene (e.g. a rabies glycoprotein gene) comprises a CAV-2 strain modified to contain the promoter-gene sequence within the region from the SmaI site close to the end of the inverted terminal repeat up to the promoter for the early region 4 (E4). To assist replication the recombinant virus is transfected into a cell line expressing Ela proteins. The recombinant virus is used for the production of a corresponding vaccine. |
| priorityDate |
1990-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |